Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Tivic Health Systems ( (TIVC) ).
On November 13, 2025, Tivic Health Systems announced the findings of a Clinical Optimization Study for its non-invasive vagus nerve stimulation device, conducted in collaboration with The Feinstein Institutes for Medical Research. The study highlighted the importance of personalizing stimulation parameters, such as frequency and electrode placement, to enhance autonomic effects, with potential clinical utility for conditions like ischemic stroke and PTSD. These findings may open new opportunities for Tivic’s product development and partnerships.
Spark’s Take on TIVC Stock
According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.
The overall stock score of 43 reflects Tivic Health Systems’ current financial difficulties, including declining revenues and negative profitability. However, recent strategic initiatives and corporate events provide some optimism for future growth. The stock’s technical indicators and valuation remain weak, necessitating significant improvements in financial performance and market sentiment to enhance stock attractiveness.
To see Spark’s full report on TIVC stock, click here.
More about Tivic Health Systems
Tivic Health Systems, Inc. is a diversified immunotherapeutics company that utilizes biopharmaceutical and bioelectronic systems to address unmet medical needs by targeting the immune system. The company is developing a non-invasive medical device for neural pathway targeting and a lead drug candidate, Entolimod™, for acute radiation syndrome, which is in late-stage development.
Average Trading Volume: 1,012,905
Technical Sentiment Signal: Sell
Current Market Cap: $3.8M
For an in-depth examination of TIVC stock, go to TipRanks’ Overview page.